Prince of Wales Hospital
Hong Kong, China
NCT Number: NCT04371276
Immunisation policies have strong influences on the epidemiology of hepatitis A and B infection. In Hong Kong, vaccines against both viruses have been available through different channels and programmes in the past 3 decades. To evaluate the changes in the prevalence of hepatitis A and B in the general population, a seroepidemiology study is conducted involving a prospective cross-sectional survey followed for serology testing. Eligible members of 1327 spatially random households would be invited to join the study by completing a questionnaire and providing blood samples, either by dried blood spots or venesection, for determining the presence of antigen and/or antibody against hepatitis B, as well as antibody against hepatitis A. The main measures comprise a set of metrics on the prevalence of hepatitis A and B. Analysis would be conducted to examine the association of risk factors with the tested markers and describe the attitudes towards viral hepatitis vaccination. The results would allow us to understand the transmission potential of hepatitis A and B in the community would be influenced by the changing disease epidemiology and coverage of vaccination, which inform the development of new vaccination strategies in Hong Kong
Looking for future studies?
Notify MeAll sexes
Observational
Hong Kong, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
Other names: blood sampling for serology testing
Time frame: 12 months
Proportion of individuals with positive HBsAg
Time frame: 12 months
Proportion of individuals with positive IgG against HAV
Chinese University of Hong Kong
Other
Evaluation of the Seroepidemiology of Hepatitis A and B in the General Population for Informing the Development of New Hepatitis Vaccination Strategies in Hong Kong
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06360484
Blood-Borne Infections, Communicable Diseases
Khartoum, Sudan
View Trial DetailsNCT04062253
Blood-Borne Infections, Communicable Diseases
Madrid, Spain
View Trial DetailsNCT01988753
Blood-Borne Infections, Communicable Diseases
Houston, Texas, United States
View Trial DetailsNCT03933384
Blood-Borne Infections, Communicable Diseases
Taichung, Taiwan
View Trial Details